Cargando…

Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control

Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forst, Thomas, Weber, Matthias M., Pfützner, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345223/ https://www.ncbi.nlm.nih.gov/pubmed/22577369 http://dx.doi.org/10.1155/2012/635472

Ejemplares similares

Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
por: Pfützner, Andreas, et al.
Publicado: (2011)

Association between glycemic control and morning blood surge with vascular endothelial dysfunction in type 2 diabetes mellitus patients
por: Nuthalapati, Rama Kumari, et al.
Publicado: (2016)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease
por: Akasaka, Tomonori, et al.
Publicado: (2017)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes
por: Forst, Thomas, et al.
Publicado: (2010)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?
por: Marx, Nikolaus, et al.
Publicado: (2018)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
por: Hanefeld, Markolf, et al.
Publicado: (2011)

The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction
por: An, Ying, et al.
Publicado: (2023)

Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination
por: Pfützner, Andreas, et al.
Publicado: (2007)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus
por: Chen, Shuai, et al.
Publicado: (2021)

Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study
por: Berndt-Zipfel, Christine, et al.
Publicado: (2013)

Acute Endothelial Benefits of Fat Restriction over Carbohydrate Restriction in Type 2 Diabetes Mellitus: Beyond Carbs and Fats
por: Barbosa-Yañez, Renate Luzía, et al.
Publicado: (2018)

GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction
por: Cai, Xiangsheng, et al.
Publicado: (2018)

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

The Main Determinants of Diabetes Mellitus Vascular Complications: Endothelial Dysfunction and Platelet Hyperaggregation
por: Carrizzo, Albino, et al.
Publicado: (2018)

Role of C-Peptide in the Regulation of Microvascular Blood Flow
por: Forst, T., et al.
Publicado: (2008)

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD
por: Shah, Hetal S., et al.
Publicado: (2018)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019)

GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells
por: Li, Quan, et al.
Publicado: (2017)

Endothelial dysfunction in diabetes mellitus
por: Hadi, Hadi AR, et al.
Publicado: (2007)

COVID-19 and Erectile Dysfunction: Endothelial Dysfunction and Beyond
por: Sansone, Andrea, et al.
Publicado: (2021)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus
por: Wei, Fang, et al.
Publicado: (2016)

Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability
por: Huang, Ye, et al.
Publicado: (2022)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
por: Ceccarelli, Elena, et al.
Publicado: (2013)

Endothelial dysfunction and cardiovascular disease
por: Widmer, R. Jay, et al.
Publicado: (2014)

Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
por: Helmstädter, Johanna, et al.
Publicado: (2020)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

GLP-1a: Going beyond Traditional Use
por: Laurindo, Lucas Fornari, et al.
Publicado: (2022)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Piccini, Sara, et al.
Publicado: (2023)

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling
por: Remm, Friederike, et al.
Publicado: (2018)

The impact of periodontitis on vascular endothelial dysfunction
por: Li, Qian, et al.
Publicado: (2022)

Vascular stiffening and endothelial dysfunction in atherosclerosis
por: Hooglugt, Aukie, et al.
Publicado: (2022)

Therapeutic potentials of oral health instructions in periodontitis patients with diabetes mellitus: Glycemic control and beyond
por: Tseng, Chih-Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_md8r9lgto5ejpsd8615ghu194k